Cotellic^® (cobimetinib)

Medical Professionals Resources

• Medical Communications
  Medical information about Genentech products.

  Phone: (800) 821-8590
  Hours: Monday - Friday 5am - 5pm PT

• Genentech Access Solutions
  This service offers coverage support, patient assistance, and other useful information.

  Genentech Patient Foundation
  Provides free medicine to patients without insurance coverage or who can't pay for their Genentech medicine.

  Cotellic.com
  Provides additional resources and information.

  Have a question about one of our medicines?
  Email us your question by using this form.

  Product Security
  Help protect your patients from counterfeit medicine.

---

Indication

COTELLIC (cobimetinib) is indicated for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, in combination with ZELBORAF (vemurafenib).

Important Safety Information

WARNINGS AND PRECAUTIONS

Review the Full Prescribing Information for ZELBORAF for information on the serious risks of ZELBORAF.

The following can occur in patients treated with COTELLIC:

• New primary malignancies, including cutaneous and non-cutaneous malignancies
• Hemorrhage, including major hemorrhages
• Cardiomyopathy, defined as symptomatic and asymptomatic decline in left ventricular ejection fraction
• Severe dermatologic reactions, including rash and other skin reactions
• Serous retinopathy and retinal vein occlusion
• Hepatotoxicity
• Rhabdomyolysis
• Severe photosensitivity
• Embryo-fetal toxicity

USE IN SPECIFIC POPULATIONS: Lactation

Do not breastfeed while taking COTELLIC and for 2 weeks after the final dose.

DRUG INTERACTIONS

Avoid concomitant administration of COTELLIC with strong or moderate CYP3A inducers or inhibitors.

Most Common Adverse Reactions

The most common (≥20%) adverse reactions with COTELLIC were diarrhea (60%), photosensitivity reaction (46%), nausea (41%), pyrexia (28%), and vomiting (24%). The most common (≥5%) Grade 3-4 laboratory abnormalities were increased GGT (21%), increased CPK (14%), hypophosphatemia (12%), increased ALT (11%), lymphopenia (10%), increased AST (8%), increased alkaline phosphatase (7%), and hyponatremia (6%).

You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at (888) 835-2555.

Please see Full COTELLIC Prescribing Information for additional Important Safety Information.